Selected data models

You must log in to select data models for download or further analysis.

11 Search results.
Relevance Rating New first Old first

dbGaP phs000853 Normative Aging Study (NAS) - Eligibility

- 3/10/24 - 5 forms, 1 itemgroup, 1 item, 1 language
Itemgroup: IG.elig
Principal Investigator: Andrea A. Baccarelli, MD, MPH, PhD, Harvard School of Public Health, Boston, MA, USA MeSH: Mortality,DNA Methylation https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000853 The Normative Aging Study (NAS) is a longitudinal study established by the United States Department of Veterans Affairs in 1963. Participants were male residents and free of chronic disease at the time of recruitment. Participants were invited to undergo an in-person examination every 3-5 years. Participants provided information on medical history, lifestyle and demographic factors and underwent a physical examination and laboratory tests, at each visit. Participants provided written informed consent at each visit, and the VA Boston Healthcare System Institutional Review Board approved the study.

pht004427.v1.p1

1 itemgroup 2 items

pht004429.v1.p1

1 itemgroup 17 items

pht004430.v1.p1

1 itemgroup 4 items

pht004428.v1.p1

1 itemgroup 3 items

Operating Room case record form (EuSOS)

- 9/20/21 - 1 form, 1 itemgroup, 40 items, 1 language
Itemgroup: Operating Room case record form
European Surgical Outcomes Study (EuSOS) http://clinicaltrials.gov/show/NCT01203605

Simplified Pulmonary Embolism Severity Index (sPESI)

- 1/25/18 - 1 form, 1 itemgroup, 7 items, 1 language
Itemgroup: sPESI
The Pulmonary Embolism Severity Index (PESI) estimates the risk of 30-day mortality in patients with acute pulmonary embolism (PE). The simplified PESI has similar prognostic accuracy and clinical utility and greater ease of use compared with the original PESI. Reference: Jiménez, D., Aujesky, D., Moores, L., Gómez, V., Lobo, J. L., Uresandi, F., ... & Yusen, R. D. (2010). Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism. Archives of internal medicine, 170(15), 1383-1389.

Pediatric Risk of Mortality (PRISM) Score for Children

- 1/25/18 - 1 form, 1 itemgroup, 15 items, 1 language
Itemgroup: PRISM score for children
"The Pediatric Risk of Mortality (PRISM) score was developed from the Physiologic Stability Index (PSI) to reduce the number of physiologic variables required for pediatric ICU (PICU) mortality risk assessment and to obtain an objective weighting of the remaining variables." Version for children(>1 year) Reference: Pollack, M. M., Ruttimann, U. E., & Getson, P. R. (1988). Pediatric risk of mortality (PRISM) score. Critical care medicine, 16(11), 1110-1116.

Pediatric Risk of Mortality (PRISM) Score for Infants

- 1/25/18 - 1 form, 1 itemgroup, 15 items, 1 language
Itemgroup: PRISM score for infants
"The Pediatric Risk of Mortality (PRISM) score was developed from the Physiologic Stability Index (PSI) to reduce the number of physiologic variables required for pediatric ICU (PICU) mortality risk assessment and to obtain an objective weighting of the remaining variables." Version for infants (0-1 year) Reference: Pollack, M. M., Ruttimann, U. E., & Getson, P. R. (1988). Pediatric risk of mortality (PRISM) score. Critical care medicine, 16(11), 1110-1116.

Form D 26072_GSK Ropinirole in Patients Suffering from Restless Legs Syndrome 101468/190

- 10/17/17 - 1 form, 1 itemgroup, 6 items, 1 language
Itemgroup: Cause of death
Study ID: 101468/190 Clinical Study ID: SKF-101468/190 Study Title:A 12 Week, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of Ropinirole in Patients Suffering from Restless Legs Syndrome (RLS). Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: Requip Study Indication: Restless Legs Syndrome This is the Form D assessment form.

Death GSK Ropinirole Restless Legs Syndrome 101468

- 9/18/17 - 1 form, 2 itemgroups, 8 items, 1 language
Itemgroups: Patient Information, Death
Study ID: 101468/207 Clinical Study ID: SKF-101468/207 Study Title:A double-blind, randomized, placebo-controlled, parallel-group study to investigate the tolerability of a dose-escalating regimen of ropinirole in patients suffering from Restless Legs Syndrome (RLS). Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 2 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: Requip Study Indication : Restless Legs Syndrome Death

Throughout: Mortality Report [MO_1] NCT01117584

- 2/4/17 - 1 form, 1 itemgroup, 4 items, 1 language
Itemgroup: General Information
NCT01117584 Astellas Phase 2b, Double-Blind, Randomized, Multicenter, Parallel Group, Placebo-Controlled, Dose-Finding Study to Evaluate the Efficacy, Safety and Tolerability of a 12- Week Treatment with ASP1941 in Combination with Metformin in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Alone.

Physiological data following 48 hours in critical care (EuSOS)

- 9/29/14 - 1 form, 1 itemgroup, 15 items, 1 language
Itemgroup: Physiological data following 48 hours in critical care
European Surgical Outcomes Study (EuSOS) http://clinicaltrials.gov/show/NCT01203605

Physiological data following 24 hours in critical care (EuSOS)

- 9/29/14 - 1 form, 1 itemgroup, 15 items, 1 language
Itemgroup: Physiological data following 24 hours in critical care
European Surgical Outcomes Study (EuSOS) http://clinicaltrials.gov/show/NCT01203605

Post-operative follow-up (EuSOS)

- 9/27/14 - 1 form, 1 itemgroup, 7 items, 1 language
Itemgroup: Post-operative follow-up
European Surgical Outcomes Study (EuSOS) http://clinicaltrials.gov/show/NCT01203605

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial